Sector Update: Health Care Stocks Mixed Premarket Thursday

Weekly Report: what happened at IBB last week (0715-0719)?

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

Gilead Sciences' Q2 2024 Earnings: What to Expect

Gilead Sciences, Inc. Is set to announce its fiscal Q2 earnings results after the market closes on Thursday, Aug. 8. The company is expected to report a profit of $1.58 per share. GILD stock has declined 9.5% on a YTD basis. The consensus opinion on the company's stock is optimistic.

HQH: Discount Remains Attractive With A Now Higher Distribution Rate

Abrdn Healthcare Investors Fund focuses on the more cyclical biotech space, with over half of its portfolio allocated there. The fund's managed distribution policy was increased significantly since our prior update. The abrdn healthcare investors fund continues to trade at an attractive discount. Discount Narrows With Distribution Increase But Remains Appealing.

ASCO Annual Meeting 2024: Breakthrough Treatments Hint At Renewed Hope For Patients And Investors

Sector Update: Health Care Stocks Rise Pre-Bell Tuesday

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Weekly Report: what happened at IBB last week (0708-0712)?

Tap Dancing Over Lava

Noteworthy ETF Outflows: IBB

Q3 2024 Equity Market Outlook

Home Market Outlook Today's Market Q3 2024 Equity Market Outlook: Neuberger Berman 2.93K Followers. We expect further corporate earnings growth across sectors, fueled by rising household net worth and a global industrial rebound. We recommend overweighting technology, communications and consumer discretionary stocks.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs

Biotech indexes lagged broader market indexes in the first half of 2024. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation is likely to trend lower, and the Fed is expected to cut rates in September. The second half of 2024 holds potential for biotech stocks to break out of their consolidation.

Weekly Report: what happened at IBB last week (0701-0705)?

Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum

Amgen shares have outperformed the iShares Biotechnology ETF by over 40% in the past year. The biotech company's shares are up more than 40% over the past 12 months. Amgen is a standout in the GLP-1 space and has strong fundamentals and technicals. The company's Q2 numbers are due out in August and the stock has a buy rating.

Global Anti-Obesity Market Analysis: Key Trends And Insights

CDT Insider Sentiment June 2024: Keep Your Seatbelt Fastened

Equity Outlook: Making Way For The Magnificent Others

Global stocks posted healthy gains in the first half of 2024. Despite narrow market concentration, we see opportunities in high-quality stocks that haven't yet been rewarded. With inflation still high and equity returns concentrated, the time may be right for investors to broaden their horizons. Equity Outlook: Making way for the Magnificent Others.

Midyear Equity Outlook - Investing Beyond The Megacaps

Home Investing Strategy Portfolio Strategy Midyear Equity Outlook - Investing Beyond The Megacaps by Nelson Yu. The best performing sector has been technology with all of the AI powering the technology gains. Inflation has actually been more selective than the world expected. Lagging the stock market is consumer, not surprisingly.